OptiBiotix Health PLC Appointment of Sales and Marketing Director (4011U)
January 18 2017 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 4011U
OptiBiotix Health PLC
18 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Sales and Marketing Director
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the appointment of Christina Wood as Sales
and Marketing Director. Christina will join the OptiBiotix Board
subject to completion of the normal regulatory due diligence.
Christina has over 20 years' sales experience within the food,
nutrition, and nutraceuticals industry. As the owner and CEO of
Confoco, a supplier of high quality food ingredients worldwide,
Christina grew the business from GBP1m to GBP10m sales by obtaining
strategic supplier status with multiple global corporates including
Nestlé, Danone, and Heinz. During this time, she developed a
network of agents and distributors across key international
markets. Christina sold her company to Diana Naturals in 2013 which
was subsequently acquired by Symrise AG for US$1.75 billion in
2014. She joined John Morley, a leading food industry supplier, in
late 2014 where as Director of Sales and Marketing, she was
responsible for key consumer accounts including Sainsbury's,
Waitrose, M&S and Tesco.
She has been a finalist for Director of the Year for 'SME and
International Trade' on two occasions and has been awarded the
Nutricia Partners in Growth Award. Christina is fluent in German
and Spanish.
Christina has extensive experience in building and managing
supply chain agreements across international markets with leading
industry players, and has both business to business, and business
to retail sales experience. Her sales and marketing experience
within the food, nutrition, and nutraceuticals industry and network
of global contacts will help grow revenues of OptiBiotix's products
across multiple application areas and international markets.
Stephen O'Hara, CEO of OptiBiotix, commented: "Christina's
experience of building sales in her own business by developing
relationships with food ingredient manufacturers and major
retailers brings new elements of operational, commercial and
industry expertise to OptiBiotix. Her skills in building and
managing international networks of agents and distributors will be
invaluable in taking OptiBiotix's patented SlimBiome(R) technology
for hunger free weight loss and its LP-LDL(R) probiotic strain for
cholesterol and hypertension reduction into overseas markets. This
will help create multiple revenue streams from OptiBiotix's growing
pipeline of products."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0883
Liam Murray
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876
741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABRMFTMBABBBR
(END) Dow Jones Newswires
January 18, 2017 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024